darbepoetin alfa

This medicine is authorised for use in the European Union.


Aranesp is a medicine used to treat anaemia (low red blood cell counts) that is causing symptoms. It is used in two groups of patients:

  • adults and children with chronic renal failure (long-term, decreasing in the ability of the kidneys to work properly);
  • adults who are receiving chemotherapy for non‑myeloid cancer (cancer not originating in the bone marrow).

Aranesp contains the active substance darbepoetin alfa.

This EPAR was last updated on 11/11/2022

Authorisation details

Product details
Agency product number
Active substance
darbepoetin alfa
International non-proprietary name (INN) or common name
darbepoetin alfa
Therapeutic area (MeSH)
  • Anemia
  • Cancer
  • Kidney Failure, Chronic
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Amgen Europe B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Minervum 7061
NL-4817 ZK Breda
The Netherlands

Product information

28/10/2022 Aranesp - EMEA/H/C/000332 - N/0162

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Other antianemic preparations

Therapeutic indication

Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients.

Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

Assessment history

Related content

How useful was this page?

Add your rating
3 ratings
1 rating
1 rating